Home GPCR & G Protein Cannabinoid Receptor

Cannabinoid Receptor Agonists

Cat.No. Product Name Information Product Use Citations Product Validations
S1544 AM1241 AM-1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, and this compound exhibits 82-fold selectivity over CB1 receptor.
Cell Rep, 2025, 44(4):115559
CNS Neurosci Ther, 2025, 31(8):e70591
Redox Rep, 2024, 29(1):2420572
Verified customer review of AM1241
S2854 BML-190 BML-190 (IMMA) is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.
International Journal of Molecular Sciences, 2020, 2259
Int J Mol Sci, 2020, 21(7)
University of Alberta, 2014, Yahya Muhammad Fiteih
Verified customer review of BML-190
S1534 Org 27569 Org 27569 is an allosteric modulator of cannabinoid CB1 receptor, induces a CB1 receptor state that is characterized by enhanced agonist affinity and decreased inverse agonist affinity.
Biochem Pharmacol, 2024, 224:116190
ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
S2778 GW842166X GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2.
Nat Commun, 2020, 11(1):71
S8017 WIN 55, 212-2 mesylate WIN 55,212-2 Mesylate ((R)-(+)-WIN 55212) is a potent cannabinoid (CB) receptor agonist with Ki of 3.3 nM and 62.3 nM for human recombinant CB2 and CB1, respectively. WIN 55,212-2 Mesylate regulates Glutamate transmission.
Eur Arch Psychiatry Clin Neurosci, 2022, 10.1007/s00406-022-01437-1
E1841 Monlunabant Monlunabant(INV-202, (S)-MRI-1891) is a peripherally acting inverse agonist of the cannabinoid type-1 receptor (CB1R), with the potential to treat respiratory and renal complications associated with metabolic disorders. It improves lung compliance in a mouse model of asthma and reduces renal fibrosis in a streptozotocin-induced diabetic nephropathy mouse model.
E4585 N-Arachidonyldopamine N-Arachidonyldopamine is a potent agonist of cannabinoid receptor 1 (CB1), with a Ki of 250 nM in rat brain membranes, showing 40-fold selectivity for CB1 over CB2 receptors. It also triggers intracellular calcium mobilization in N18TG2 neuroblastoma cells.
S0412 Bay 59-3074 Bay 59-3074 is a selective cannabinoid CB1/CB2 receptor partial agonist with Ki of 55.4 nM, 48.3 nM and 45.5 nM at rat and human CB1 and human CB2 receptors, respectively. This compound displays analgesic properties.